2889 Nystatin Nystatin is an exogenous solid compound with the chemical formula C47H75NO17. Nystatin belongs to the carbohydrates and carbohydrate conjugates, a subclass of organooxygen compounds within the organic compounds. With an average molecular weight of 926.11 g/mol, Nystatin is a heavy molecule. This polyene antifungal drug is effective against many yeasts and molds, including Candida spp. While it is considered a relatively safe drug for treating gastrointestinal or oral fungal infections, it is not absorbed across mucous membranes or intact skin. However, toxicity is associated with the drug when administered intravenously. Recorded exposure routes for the compound include topical, oral, vaginal, and inhalation. Nystatin is found in or released from twelve recorded sources. Within healthcare, pharmaceuticals, and veterinary products, it is utilized as an antibiotic, a gynecological agent, an intestinal antiinfective, a component in combinations of antibacterials, and an antifungal for dermatological use. Additionally, it is associated with household cleaning and consumer products, specifically other smoking requisites. It is also found in food, food processing, and cookware, including the preparation of vinegar, wort, and malt. Further recorded sources include electrical and electronic equipment, such as thin magnetic films, electric hearing aids, and antennas. 1400-61-9 11953884 C47H75NO17 925.503500 White powder. 160°C 360 mg/L (at 24°C) Oral, topical(intravaginal). Nystatin is not absorbed from intact skin or mucous membrane. Nystatin interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary for the conversion of lanosterol to ergosterol. This results in inhibition of ergosterol synthesis and increased fungal cellular permeability. Nystatin exerts its antifungal activity by binding to ergosterol found in fungal cell membranes. Binding to ergosterol causes the formation of pores in the membrane. Potassium and other cellular constituents leak from the pores causing cell death. No indication of carcinogenicity to humans (not listed by IARC). Used to treat cutaneous, vaginal, mucosal and esophageal Candida infections. Nystatin is often used as prophylaxis in patients who are at risk for fungal infections, such as AIDS patients with a low CD4+ count and patients receiving chemotherapy.[Wikipedia] Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported. Stevens-Johnson syndrome has been reported very rarely. (L1873) Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances. Rash, including urticaria has been reported rarely. (L1873) 2009-07-21T20:27:19Z 2026-05-14T16:44:58Z Nystatin C06572 7660 Nystatin DB00646 true [H]C1=C([H])C([H])=C([H])C(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CC(O)CCC(O)C(O)CC(=O)CC(O)C(C(O)CC(OC2OC(C)C(O)C(N)C2O)\C([H])=C(\[H])/C(/[H])=C(\[H])/C(/[H])=C(\[H])/C(/[H])=C([H])/CC1)C(O)=O C47H75NO17 InChI=1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-35(65-47-45(60)42(48)44(59)30(4)64-47)26-39(56)41(46(61)62)38(55)24-34(52)23-37(54)36(53)20-19-31(49)21-32(50)22-33(51)25-40(57)63-29(3)28(2)43(27)58/h5-6,8,10-18,27-33,35-39,41-45,47,49-51,53-56,58-60H,7,9,19-26,48H2,1-4H3,(H,61,62)/b6-5+,10-8+,13-11+,14-12+,17-15+,18-16- ZDFDJJJGIRGMBE-UZHOVVQJSA-N 926.107 925.503499959 Exogenous Solid 0.5 HMDB14784 CHEMBL229383 10128183 CHEM002236 DTXSID4040688 NS00000545 (1S,3R,4R,7R,9R,11R,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E,33R,35S,36R,37S)-33-{[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid 327.45000000000005 245.1750000000001 28.721938535450253 3 17 12 3.6208467022216593 9.11381640698386 0 2 -2.82 -4.15 6.60e-02 g/l Organic compounds Organic oxygen compounds Organooxygen compounds Carbohydrates and carbohydrate conjugates 5908 CED0002323 ZDFDJJJGIRGMBE-IISDKMBCSA-N 10000080000800008000000000000000000000000000000020004100000400000000000000200001800000000000040000000000000002000000000000000000050002000200000300000000000000208000000001000000200000020000000000802900000000004002040020000000000200000000002000000000001000000020500000108044000000800014000010000008000000000000004000000008008400140000000000000c0000000000010000000200040100000000000000000000010000000000000008000800000000000200000000000000000000000000000000c00000100040050000000440000000048080000000000000000000 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 776t3gAAAAAQAAAAAwAAAAAAAABBAAAAQgAAAIABBgA4AAAAAwEEBgA4AAAA AwEEBgA4AAAAAwEEBgA4AAAAAwEEBgBgAAAAAwEGAGAAAAABAwYAYAAAAAMB CABgAAAAAQEGAGAAAAADAQYAYAAAAAEDBgBgAAAAAwEGAGAAAAABAwgAKAAA AAMCBgAoAAAAAwQIACgAAAADAgYAYAAAAAICBgBgAAAAAwEIAGAAAAABAQYA YAAAAAICBgBgAAAAAwEIAGAAAAABAQYAYAAAAAICBgBgAAAAAwEIAGAAAAAB AQYAYAAAAAICBgBgAAAAAgIGAGAAAAADAQgAYAAAAAEBBgBgAAAAAwEIAGAA AAABAQYAYAAAAAICBgAoAAAAAwQIACgAAAADAgYAYAAAAAICBgBgAAAAAwEI AGAAAAABAQYAYAAAAAMBBgBgAAAAAwEIAGAAAAABAQYAYAAAAAICBgBgAAAA AwEIACAAAAACBgBgAAAAAwEIACAAAAACBgBgAAAAAwEGAGAAAAABAwYAYAAA AAMBCABgAAAAAQEGAGAAAAADAQcAYAAAAAECBgBgAAAAAwEIAGAAAAABAQYA OAAAAAMBBAYAOAAAAAMBBAYAOAAAAAMBBAYAOAAAAAMBBAYAOAAAAAMBBAYA OAAAAAMBBAYAOAAAAAMBBAYAOAAAAAMBBAYAYAAAAAICBgBgAAAAAgIGACgA AAADBAgAaAAAAAMBAQgAKAAAAAMCCwABKAIBAiACAygCAwQABAUABAYABgcA BggACAkACAoACgsACgwADA0gDQ4oAg0PAA8QABARABASABITABMUABMVABUW ABYXABYYABgZABkaABobABocABwdABweAB4fAB8gCAIfIQAhIgAiIwAiJAAk JQAlJgAlJwAnKAAoKQApKgAqKwArLAAsLQAsLgAuLwAuMAAwMQAwMgAyMwAo NAQDNDUqAgICKDY1NiQENjcqAgMCNTg3OCQEODkqAgMCNzo5OiQEOjsqAgMC OTw7PAQEPD0AJD4APj8gPkAoAj0AADIqAEICAAAAJgA9PDs6OTg3NjU0KCcl JCIhHx4cGhkYFhUTEhAPDQwKCAYEAwIBBissLjAyKhcEAAAAAAAAABY= 2026-09-19T04:00:36Z